Уважаемые пользователи!

Данный сайт содержит информацию для людей с медицинским образованием и специалистов здравоохранения.
Входя на сайт, Вы подтверждаете свое согласие с Условиями использования и Политикой конфиденциальности.



Dear visitor!
This site contains medical information for healthcare professionals.
You can go further, if you agree with Terms and Conditions and Privacy Policy on this site.

The influence of orlistat (Xenical) therapy on the parameters of lipid metabolism in patients with obesity

Cover Page

Abstract


One of the main goals in treatment of obesity is descending of overall cardiometabolic risk, which is mostly defined by atherogenic changes in blood lipid spectrum. Scientific data, presented in this review confirm that orlistat is effective for treatment of obesity, its introduction significantly increases proportion of patients who reach clinically valuable results. The mechanism of action of orlistat explains its influence on parameters of blood lipids, which doesn't directly depend on the decrease of body mass during treatment. Improvement of cardiometabolic parameters during orlistsat treatment allows to consider this therapy as one of the methods for correction of dyslipidemia

  • Brixner D., Ghate S., McAdam-Marx C. et al. Association between cardiometabolic risk factors and body mass index based on diagnosis and treatment codes in an electronic medical record database. JMPC 2008, 14(8): 756-767.
  • Datillo A., Kris-Etherton P. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992, 56: 320-328.
  • Depres J-P., Poirier P., Bergeron J. et al. From individual risk factors and the metabolic syndrome to global cardiometabolic risk. European Heart Journal 2008, 10(suppl B): B24-B33.
  • Derosa G., Mugellini A., Cicarelli L. et al. Randomized, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 2003, 25(4): 1107-1122.
  • Eleftheriadou I., Grigoropoulou P., Katsilambros N. et al. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism. Current Diabetes Reviews 2008, 4(4): 340-356.
  • Filippatos T., Kiortsis D., Liberopoulus E. et al. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005, 21(12): 1997-2006.
  • Hollander P., Elbein S., Hirsch I. et al. Role of orlistat in the treatment of obese patients with Type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998, 21(8): 1288-1294.
  • Hutton B., Fergusson D. Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am. J. Clin. Nutr. 2004, 80(6):1461-1468.
  • Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med 1999, 246: 314-355.
  • Leenen R., van der Kooy K., Meyboom S. et al. Relative effects of weight loss and dietary fat modification on serum lipid levels in the dietary treatment of obesity. J Lip Res 1993, 34: 2183-2191.
  • Lucas K., Kaplan-Machlis B. Orlistat - a novel weight loss therapy. Ann. Pharmacother. 2001, 35(3): 314-328.
  • Lucas C., Boldrin M., Reaven G. Effect of orlistat added to diet (30 % of calories from fat) on plasma lipids, glucose and insulin in obese patients with hypercholesterolemia. Am. J. Cardiol. 2003, 91(8): 961-964.
  • Micic D., Ivkovic-Lazar T., Dragojevic R. et al. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidaemia. Med. Pregl. 1999, 52(9-10): 323-333.
  • Mittendorfer B., Ostlundre J., Patterson B. et al. Orlistat inhibits dietary cholesterol absorption. Obes Res 2001, 9(10): 599-604.
  • Muls E., Kolanovski J., Scheen A. et al. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo controlled multicentral study. Int J Obes Relat Metab Disord 2001, 25: 1713-1721.
  • Must A., Spadano J., Coakley E. et al. The disease burden associated with overweight and obesity. JAMA 1999, 282, 1523-1529.
  • Rucker D., Padwal R., Li S. et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis BMJ 2007; 335: 1194-1199.
  • Suter P., Marmier G., Veya-Linder C. et al. Effect of orlistat on postprandial lipaemia, NMR lipoprotein subclass profiles and partical size. Atherosclerosis 2005, 180(1): 127-135.
  • Tan K., Tso A., Tam S. et al. Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus. Diabet. Med. 2002, 19(11): 944-948.
  • Tonstad S., Pometta D., Erkelens D. et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur.J Clin. Pharmacol. 1994, 46(5): 405-410.
  • Wirth A. Reduction of body weight and co-morbidities by orlistat: The XXL-Primary Health Care Trial. Diab Obes Metab 2005, 7:21-27.
  • Zavoral J. Treatment with orlistat reduces cardiovascular risk in obese patients. J. Hypertens. 1998, 16(12 pt 2): 2013-2017.

Views

Abstract - 747

PDF (Russian) - 81


Copyright (c) 2009 Mazurina N.V., Masurina N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.